首页 > 最新文献

Journal of Surgical Oncology最新文献

英文 中文
Letter to the Editor: Marginal Resection Is Appropriate for Radical Surgery for Solitary Fibrous Tumors of the Pelvis. 致编辑的信:骨盆孤立性纤维性肿瘤的根治性手术宜采用边缘切除。
IF 1.9 3区 医学 Q3 ONCOLOGY Pub Date : 2025-12-29 DOI: 10.1002/jso.70149
Humna Minhas, Abdullah Hameed
{"title":"Letter to the Editor: Marginal Resection Is Appropriate for Radical Surgery for Solitary Fibrous Tumors of the Pelvis.","authors":"Humna Minhas, Abdullah Hameed","doi":"10.1002/jso.70149","DOIUrl":"https://doi.org/10.1002/jso.70149","url":null,"abstract":"","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145856710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical Outcomes and Surgical Procedures for Patients With Osteosarcoma and Metachronous Lung Metastasis: A Chronological Analysis. 骨肉瘤和异时性肺转移患者的临床结果和外科手术:时间顺序分析。
IF 1.9 3区 医学 Q3 ONCOLOGY Pub Date : 2025-12-25 DOI: 10.1002/jso.70152
Kazuha Nakabachi, Hirokazu Shimizu, Masatake Matsuoka, Tamotsu Soma, Hirofumi Adachi, Yasushi Mizukami, Norimasa Iwasaki, Akira Iwata, Hiroaki Hiraga

Background and objectives: Osteosarcoma (OS) survival rates have remained unchanged for decades, while video-assisted thoracic surgery (VATS) for lung metastasis (LM) became common. We aimed to clarify clinical outcomes of post-relapse survival (PRS) for patients with OS based on LM-free survival (LMFS) across different eras.

Methods: This single-centre retrospective study included 168 patients with OS without LM at initial diagnosis. Patients were categorised into three groups: non-LM (n = 89), synchronous LM (sLM: less than 1-year LMFS) (n = 40), and mLM (at least 1-year LMFS) (n = 39). We compared PRS in patients with sLM and mLM across periods 1 (1990-2005) and 2 (2006-2022).

Results: PRS for mLM was longer in period 2 than in period 1 (Hazard ratio: 0.37, 95% confidence interval: 0.12-0.97, p = 0.04), whereas no difference was observed for sLM. In mLM, ratios of surgery, radiotherapy, and chemotherapy were unchanged; the rate of VATS increased in period 2 (7/18 vs. 10/12, p = 0.01). The rate of reoperation remained unchanged (7/18 vs. 7/12, p = 0.39).

Conclusions: In period 2, mLM had a better prognosis than in period 1. There was an increased use of VATS, while the rates of reoperation for LM remained unchanged. Conversely, the prognosis for sLM was not altered.

背景和目的:骨肉瘤(OS)的生存率几十年来一直保持不变,而视频辅助胸外科手术(VATS)治疗肺转移(LM)变得普遍。我们的目的是基于不同时期的无lm生存期(LMFS)来阐明OS患者复发后生存期(PRS)的临床结果。方法:本单中心回顾性研究纳入168例初诊无LM的OS患者。患者分为三组:非LM (n = 89),同步LM (sLM:少于1年的LMFS) (n = 40)和mLM(至少1年的LMFS) (n = 39)。我们比较了第1期(1990-2005)和第2期(2006-2022)sLM和mLM患者的PRS。结果:第二阶段mLM的PRS比第一阶段长(风险比:0.37,95%可信区间:0.12-0.97,p = 0.04),而sLM无差异。在mLM中,手术、放疗和化疗的比例不变;第2期VATS发生率升高(7/18 vs 10/12, p = 0.01)。再手术率保持不变(7/18 vs. 7/12, p = 0.39)。结论:2期mLM预后优于1期。VATS的使用增加,而LM的再手术率保持不变。相反,sLM的预后没有改变。
{"title":"Clinical Outcomes and Surgical Procedures for Patients With Osteosarcoma and Metachronous Lung Metastasis: A Chronological Analysis.","authors":"Kazuha Nakabachi, Hirokazu Shimizu, Masatake Matsuoka, Tamotsu Soma, Hirofumi Adachi, Yasushi Mizukami, Norimasa Iwasaki, Akira Iwata, Hiroaki Hiraga","doi":"10.1002/jso.70152","DOIUrl":"https://doi.org/10.1002/jso.70152","url":null,"abstract":"<p><strong>Background and objectives: </strong>Osteosarcoma (OS) survival rates have remained unchanged for decades, while video-assisted thoracic surgery (VATS) for lung metastasis (LM) became common. We aimed to clarify clinical outcomes of post-relapse survival (PRS) for patients with OS based on LM-free survival (LMFS) across different eras.</p><p><strong>Methods: </strong>This single-centre retrospective study included 168 patients with OS without LM at initial diagnosis. Patients were categorised into three groups: non-LM (n = 89), synchronous LM (sLM: less than 1-year LMFS) (n = 40), and mLM (at least 1-year LMFS) (n = 39). We compared PRS in patients with sLM and mLM across periods 1 (1990-2005) and 2 (2006-2022).</p><p><strong>Results: </strong>PRS for mLM was longer in period 2 than in period 1 (Hazard ratio: 0.37, 95% confidence interval: 0.12-0.97, p = 0.04), whereas no difference was observed for sLM. In mLM, ratios of surgery, radiotherapy, and chemotherapy were unchanged; the rate of VATS increased in period 2 (7/18 vs. 10/12, p = 0.01). The rate of reoperation remained unchanged (7/18 vs. 7/12, p = 0.39).</p><p><strong>Conclusions: </strong>In period 2, mLM had a better prognosis than in period 1. There was an increased use of VATS, while the rates of reoperation for LM remained unchanged. Conversely, the prognosis for sLM was not altered.</p>","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145827941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Survival Disparities in Early-Onset Pancreatic Cancer (EOPC): The Role of Socioeconomic Status and Healthcare Access. 早发性胰腺癌(EOPC)的生存差异:社会经济地位和医疗保健获取的作用
IF 1.9 3区 医学 Q3 ONCOLOGY Pub Date : 2025-12-23 DOI: 10.1002/jso.70148
Abdullah Khalid, Ali Anjum Fazal, Manav Shah, Danielle DePeralta, Sepideh Gholami, Elliot Newman, Marcovalerio Melis, Matthew J Weiss

Introduction: Early-onset pancreatic cancer (EOPC), defined as pancreatic ductal adenocarcinoma (PDAC) diagnosed at or before age 50, is an increasingly recognized clinical entity with a rising incidence. Despite advancements in treatment, socioeconomic status (SES) disparities have impacted access to care and survival. This study examined the relationship between SES and survival in EOPC.

Methods: Data from the National Cancer Database (2004-2022) were analyzed for patients diagnosed with EOPC. SES was determined using a composite measure incorporating education and income levels and was categorized into four quartiles. Kaplan-Meier survival analysis and multivariable Cox proportional hazards modeling were used to assess survival differences across the SES groups.

Results: A total of 10,729 patients with EOPC were included, with 24.0% in the low SES group, 29.9% in mid-low SES, 30.3% in mid-high SES, and 15.8% in high SES. Higher SES was associated with increased access to multimodal therapy, including neoadjuvant and adjuvant chemotherapy, radiation, and surgical resection (p < 0.001). Private insurance coverage was significantly higher in the high-SES group (81.1% vs. 50.2% in the low-SES group, p < 0.001). Multivariable Cox regression showed that patients in the high-SES group had a significantly lower risk of mortality (HR = 0.71, 95% CI: 0.54-0.83; p = 0.033). The median survival increased from 9 months in the low SES group to 12 months in the high SES group (p < 0.001). Kaplan-Meier analysis showed that survival differences by SES were most pronounced in advanced-stage disease, particularly in stage III (p = 0.017) and stage IV (p < 0.001) cancers.

Conclusion: Lower SES was consistently linked to worse EOPC survival, particularly in advanced stages. Addressing SES-related disparities through targeted interventions and healthcare policy reforms could improve outcomes across all disease stages. Further research into the unique tumor biology and molecular characteristics of EOPC is needed to better understand how SES influences disease progression and treatment response.

早发性胰腺癌(EOPC),定义为50岁或50岁之前诊断出的胰腺导管腺癌(PDAC),是一个越来越被认可的临床实体,发病率不断上升。尽管在治疗方面取得了进步,但社会经济地位(SES)的差距影响了获得护理和生存的机会。本研究探讨了EOPC患者SES与生存的关系。方法:分析国家癌症数据库(2004-2022)中诊断为EOPC的患者的数据。社会经济地位是通过综合教育和收入水平来确定的,并分为四个四分位数。Kaplan-Meier生存分析和多变量Cox比例风险模型用于评估SES组间的生存差异。结果:共纳入EOPC患者10729例,其中低经济地位组24.0%,中低经济地位组29.9%,中高经济地位组30.3%,高经济地位组15.8%。较高的SES与多模式治疗的增加相关,包括新辅助和辅助化疗、放疗和手术切除(p结论:较低的SES始终与较差的EOPC生存有关,特别是在晚期。通过有针对性的干预措施和医疗保健政策改革来解决与ses相关的差异,可以改善所有疾病阶段的结果。需要进一步研究EOPC独特的肿瘤生物学和分子特征,以更好地了解SES如何影响疾病进展和治疗反应。
{"title":"Survival Disparities in Early-Onset Pancreatic Cancer (EOPC): The Role of Socioeconomic Status and Healthcare Access.","authors":"Abdullah Khalid, Ali Anjum Fazal, Manav Shah, Danielle DePeralta, Sepideh Gholami, Elliot Newman, Marcovalerio Melis, Matthew J Weiss","doi":"10.1002/jso.70148","DOIUrl":"https://doi.org/10.1002/jso.70148","url":null,"abstract":"<p><strong>Introduction: </strong>Early-onset pancreatic cancer (EOPC), defined as pancreatic ductal adenocarcinoma (PDAC) diagnosed at or before age 50, is an increasingly recognized clinical entity with a rising incidence. Despite advancements in treatment, socioeconomic status (SES) disparities have impacted access to care and survival. This study examined the relationship between SES and survival in EOPC.</p><p><strong>Methods: </strong>Data from the National Cancer Database (2004-2022) were analyzed for patients diagnosed with EOPC. SES was determined using a composite measure incorporating education and income levels and was categorized into four quartiles. Kaplan-Meier survival analysis and multivariable Cox proportional hazards modeling were used to assess survival differences across the SES groups.</p><p><strong>Results: </strong>A total of 10,729 patients with EOPC were included, with 24.0% in the low SES group, 29.9% in mid-low SES, 30.3% in mid-high SES, and 15.8% in high SES. Higher SES was associated with increased access to multimodal therapy, including neoadjuvant and adjuvant chemotherapy, radiation, and surgical resection (p < 0.001). Private insurance coverage was significantly higher in the high-SES group (81.1% vs. 50.2% in the low-SES group, p < 0.001). Multivariable Cox regression showed that patients in the high-SES group had a significantly lower risk of mortality (HR = 0.71, 95% CI: 0.54-0.83; p = 0.033). The median survival increased from 9 months in the low SES group to 12 months in the high SES group (p < 0.001). Kaplan-Meier analysis showed that survival differences by SES were most pronounced in advanced-stage disease, particularly in stage III (p = 0.017) and stage IV (p < 0.001) cancers.</p><p><strong>Conclusion: </strong>Lower SES was consistently linked to worse EOPC survival, particularly in advanced stages. Addressing SES-related disparities through targeted interventions and healthcare policy reforms could improve outcomes across all disease stages. Further research into the unique tumor biology and molecular characteristics of EOPC is needed to better understand how SES influences disease progression and treatment response.</p>","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145810346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Fibula Free Flap for Salvage of Complications After Orthopedic Extremity Bony Fixation in Oncologic Patients. 游离腓骨皮瓣修复肿瘤患者肢体骨固定术后并发症。
IF 1.9 3区 医学 Q3 ONCOLOGY Pub Date : 2025-12-23 DOI: 10.1002/jso.70170
Jacob Levy, Francis D Graziano, Ronnie L Shammas, Evan Matros, Michelle Coriddi, Joseph J Disa, Babak J Mehrara, Peter G Cordeiro, Farooq Shahzad

Background: Advances in orthopedic oncology have significantly improved outcomes following extremity tumor resections; however, complications like nonunion, hardware failure, and radiation-induced fractures can occur after orthopedic fixation. While the vascularized fibula-free flap (FFF) is well-established in primary reconstructions, its effectiveness as a salvage option is not well described. We report our 25-year experience with the use of FFF in salvage extremity reconstruction.

Methods: This retrospective case series included patients undergoing extremity salvage with FFF after failure of primary oncologic reconstructions from 1995 to 2021. Demographics, surgical indications, reconstructive details, functional outcomes, complications, and Musculoskeletal Tumor Society (MSTS) scores were analyzed.

Results: Fifteen patients (ages 6-71 years) met inclusion criteria, which included nine humeral and six femoral reconstructions, with an average follow-up of 6.7 years. Indications for salvage were radiation-induced fracture (n = 6), nonunion (n = 3), allograft fracture (n = 3), and hardware failure (n = 3). The median interval between the initial surgery for tumor resection and FFF for limb salvage was 4 years 3 months (mean: 9 years, range: 10 months to 29.3 years). All lower-extremity reconstructions achieved full weight-bearing without pain. Upper-extremity reconstructions resulted in full functional restoration in six patients and minor functional deficits in three. Bony union of fibula flap was achieved in 78.5% patients. Reoperation were performed in 4 patients for wound issues (n = 2) and hardware removal (n = 2).

Conclusion: FFF is a reliable and effective option for management of oncologic-related complications of the extremities. It can avoid amputations and improve limb function.

背景:骨科肿瘤学的进展显著改善了肢体肿瘤切除术后的预后;然而,骨不愈合、硬体失效和放射性骨折等并发症可在骨科固定后发生。虽然带血管的无腓骨皮瓣(FFF)在初级重建中得到了很好的应用,但其作为修复选择的有效性尚未得到很好的描述。我们报告了我们25年来使用FFF进行残救性肢体重建的经验。方法:本回顾性病例系列包括1995年至2021年原发性肿瘤重建失败后接受FFF肢体修复的患者。分析了人口统计学、手术指征、重建细节、功能结局、并发症和肌肉骨骼肿瘤学会(MSTS)评分。结果:15例患者(年龄6-71岁)符合纳入标准,包括9例肱骨重建和6例股骨重建,平均随访6.7年。抢救指征包括放射性骨折(n = 6)、骨不连(n = 3)、同种异体移植骨折(n = 3)和硬体失效(n = 3)。从首次手术切除肿瘤到FFF保肢的中位时间间隔为4年3个月(平均9年,范围10个月至29.3年)。所有的下肢重建都实现了完全的负重,没有疼痛。上肢重建导致6例患者功能完全恢复,3例患者有轻微功能缺陷。78.5%的患者腓骨瓣骨愈合。4例患者因伤口问题(n = 2)和硬体取出(n = 2)再次手术。结论:FFF是治疗四肢肿瘤相关并发症的一种可靠有效的选择。可避免截肢,改善肢体功能。
{"title":"The Fibula Free Flap for Salvage of Complications After Orthopedic Extremity Bony Fixation in Oncologic Patients.","authors":"Jacob Levy, Francis D Graziano, Ronnie L Shammas, Evan Matros, Michelle Coriddi, Joseph J Disa, Babak J Mehrara, Peter G Cordeiro, Farooq Shahzad","doi":"10.1002/jso.70170","DOIUrl":"https://doi.org/10.1002/jso.70170","url":null,"abstract":"<p><strong>Background: </strong>Advances in orthopedic oncology have significantly improved outcomes following extremity tumor resections; however, complications like nonunion, hardware failure, and radiation-induced fractures can occur after orthopedic fixation. While the vascularized fibula-free flap (FFF) is well-established in primary reconstructions, its effectiveness as a salvage option is not well described. We report our 25-year experience with the use of FFF in salvage extremity reconstruction.</p><p><strong>Methods: </strong>This retrospective case series included patients undergoing extremity salvage with FFF after failure of primary oncologic reconstructions from 1995 to 2021. Demographics, surgical indications, reconstructive details, functional outcomes, complications, and Musculoskeletal Tumor Society (MSTS) scores were analyzed.</p><p><strong>Results: </strong>Fifteen patients (ages 6-71 years) met inclusion criteria, which included nine humeral and six femoral reconstructions, with an average follow-up of 6.7 years. Indications for salvage were radiation-induced fracture (n = 6), nonunion (n = 3), allograft fracture (n = 3), and hardware failure (n = 3). The median interval between the initial surgery for tumor resection and FFF for limb salvage was 4 years 3 months (mean: 9 years, range: 10 months to 29.3 years). All lower-extremity reconstructions achieved full weight-bearing without pain. Upper-extremity reconstructions resulted in full functional restoration in six patients and minor functional deficits in three. Bony union of fibula flap was achieved in 78.5% patients. Reoperation were performed in 4 patients for wound issues (n = 2) and hardware removal (n = 2).</p><p><strong>Conclusion: </strong>FFF is a reliable and effective option for management of oncologic-related complications of the extremities. It can avoid amputations and improve limb function.</p>","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145810366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reassessing Evidence on Omitting Radiotherapy After Breast-Conserving Surgery. 保乳手术后省略放疗的证据再评估。
IF 1.9 3区 医学 Q3 ONCOLOGY Pub Date : 2025-12-23 DOI: 10.1002/jso.70168
Kadri Altundag
{"title":"Reassessing Evidence on Omitting Radiotherapy After Breast-Conserving Surgery.","authors":"Kadri Altundag","doi":"10.1002/jso.70168","DOIUrl":"https://doi.org/10.1002/jso.70168","url":null,"abstract":"","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145810358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of Circulating miR-155, miR-221, miR-34a, and miR-143 for Monitoring Tumor Clearance After Surgery in Colorectal Cancer. 评价结直肠癌术后循环miR-155、miR-221、miR-34a和miR-143对肿瘤清除的监测
IF 1.9 3区 医学 Q3 ONCOLOGY Pub Date : 2025-12-22 DOI: 10.1002/jso.70166
Hersh Abdul Ham-Karim

Background: Colorectal cancer (CRC) remains one of the leading causes of cancer-related mortality worldwide. Despite advances in surgery and adjuvant therapy, recurrence after curative resection remains a major challenge, and current surveillance tools such as carcinoembryonic antigen (CEA) and imaging lack sensitivity for detecting minimal residual disease (MRD). Circulating microRNAs (miRNAs) have emerged as promising biomarkers due to their stability in plasma and disease-specific expression profiles.

Objective: This study aimed to evaluate the clinical relevance of four circulating cell-free miRNAs-miR-155, miR-221, miR-34a, and miR-143-for monitoring tumor clearance following surgery in CRC patients.

Methods: Plasma samples were obtained from CRC patients at multiple perioperative time points and compared with samples from healthy controls. Expression levels of the selected miRNAs were quantified using real-time PCR, normalized to cel-miR-39, and analyzed in relation to clinicopathological features. Dynamic postoperative changes and diagnostic performance were assessed, including ROC curve analysis.

Results: Circulating miR-155 and miR-221 were significantly upregulated in CRC patients compared with controls, whereas the tumor suppressor miRNAs miR-34a and miR-143 were markedly downregulated. Postoperative samples showed progressive normalization of these markers, though variability persisted in a subset of patients. The combined four-miRNA panel achieved excellent diagnostic accuracy (AUC = 0.999), outperforming CEA in distinguishing CRC from controls. No independent predictive effect of individual miRNAs was demonstrated in multivariate models, but biologically consistent trends were observed.

Conclusion: Circulating miR-155, miR-221, miR-34a, and miR-143 demonstrate dynamic early postoperative changes and hold promise as minimally invasive biomarkers of short-term tumor clearance after colorectal cancer surgery. While the combined panel shows strong diagnostic performance at baseline, longer-term prospective studies with multi-year follow-up are required to establish their role in recurrence surveillance alongside established markers such as CEA and ctDNA.

背景:结直肠癌(CRC)仍然是全球癌症相关死亡的主要原因之一。尽管手术和辅助治疗取得了进展,但治愈性切除后的复发仍然是一个主要挑战,目前的监测工具,如癌胚抗原(CEA)和成像缺乏检测微小残留病(MRD)的敏感性。由于其在血浆和疾病特异性表达谱中的稳定性,循环microRNAs (miRNAs)已成为有前途的生物标志物。目的:本研究旨在评估四种循环无细胞mirna - mir -155、miR-221、miR-34a和mir -143在监测结直肠癌患者手术后肿瘤清除方面的临床意义。方法:收集结直肠癌患者围手术期多个时间点的血浆样本,并与健康对照进行比较。所选mirna的表达水平使用实时PCR进行量化,归一化为cell - mir -39,并分析其与临床病理特征的关系。评估术后动态变化及诊断效能,包括ROC曲线分析。结果:与对照组相比,循环miR-155和miR-221在结直肠癌患者中显著上调,而肿瘤抑制miRNAs miR-34a和miR-143明显下调。术后样本显示这些标志物逐渐正常化,尽管在一部分患者中变异性持续存在。联合四mirna面板获得了极好的诊断准确性(AUC = 0.999),在区分CRC和对照组方面优于CEA。在多变量模型中没有证明单个mirna的独立预测作用,但观察到生物学上一致的趋势。结论:循环miR-155、miR-221、miR-34a和miR-143在术后早期表现出动态变化,有望作为结直肠癌术后短期肿瘤清除的微创生物标志物。虽然联合组在基线时显示出强大的诊断性能,但需要进行多年随访的长期前瞻性研究,以确定其与CEA和ctDNA等已建立的标志物一起在复发监测中的作用。
{"title":"Evaluation of Circulating miR-155, miR-221, miR-34a, and miR-143 for Monitoring Tumor Clearance After Surgery in Colorectal Cancer.","authors":"Hersh Abdul Ham-Karim","doi":"10.1002/jso.70166","DOIUrl":"https://doi.org/10.1002/jso.70166","url":null,"abstract":"<p><strong>Background: </strong>Colorectal cancer (CRC) remains one of the leading causes of cancer-related mortality worldwide. Despite advances in surgery and adjuvant therapy, recurrence after curative resection remains a major challenge, and current surveillance tools such as carcinoembryonic antigen (CEA) and imaging lack sensitivity for detecting minimal residual disease (MRD). Circulating microRNAs (miRNAs) have emerged as promising biomarkers due to their stability in plasma and disease-specific expression profiles.</p><p><strong>Objective: </strong>This study aimed to evaluate the clinical relevance of four circulating cell-free miRNAs-miR-155, miR-221, miR-34a, and miR-143-for monitoring tumor clearance following surgery in CRC patients.</p><p><strong>Methods: </strong>Plasma samples were obtained from CRC patients at multiple perioperative time points and compared with samples from healthy controls. Expression levels of the selected miRNAs were quantified using real-time PCR, normalized to cel-miR-39, and analyzed in relation to clinicopathological features. Dynamic postoperative changes and diagnostic performance were assessed, including ROC curve analysis.</p><p><strong>Results: </strong>Circulating miR-155 and miR-221 were significantly upregulated in CRC patients compared with controls, whereas the tumor suppressor miRNAs miR-34a and miR-143 were markedly downregulated. Postoperative samples showed progressive normalization of these markers, though variability persisted in a subset of patients. The combined four-miRNA panel achieved excellent diagnostic accuracy (AUC = 0.999), outperforming CEA in distinguishing CRC from controls. No independent predictive effect of individual miRNAs was demonstrated in multivariate models, but biologically consistent trends were observed.</p><p><strong>Conclusion: </strong>Circulating miR-155, miR-221, miR-34a, and miR-143 demonstrate dynamic early postoperative changes and hold promise as minimally invasive biomarkers of short-term tumor clearance after colorectal cancer surgery. While the combined panel shows strong diagnostic performance at baseline, longer-term prospective studies with multi-year follow-up are required to establish their role in recurrence surveillance alongside established markers such as CEA and ctDNA.</p>","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145804860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Neoadjuvant Chemotherapy in Resectable Biliary Tract Cancer: A Systematic Review and Metanalysis. 可切除胆道癌的新辅助化疗:系统回顾和荟萃分析。
IF 1.9 3区 医学 Q3 ONCOLOGY Pub Date : 2025-12-22 DOI: 10.1002/jso.70169
Rafael Alvim Pereira, Gabriel Barcellos, Gabriel Lenz, Allan Andresson Lima Pereira, Tiago Biachi de Castria

Background and objectives: The benefit of neoadjuvant chemotherapy in resectable biliary tract cancer remains unclear.

Methods: A systematic review and meta-analysis of 23 studies (n = 11,344) compared neoadjuvant chemotherapy with upfront surgery.

Results: Neoadjuvant therapy improved overall survival (HR = 0.69) and R0 resection rates (OR = 1.30) without increasing postoperative morbidity or mortality.

Conclusions: Neoadjuvant chemotherapy may improve survival and surgical outcomes in resectable biliary tract cancer.

背景和目的:新辅助化疗治疗可切除胆道癌的益处尚不清楚。方法:对23项研究(n = 11,344)进行系统回顾和荟萃分析,比较新辅助化疗与前期手术。结果:新辅助治疗提高了总生存率(HR = 0.69)和R0切除率(OR = 1.30),且未增加术后发病率或死亡率。结论:新辅助化疗可提高可切除胆道癌患者的生存率和手术效果。
{"title":"Neoadjuvant Chemotherapy in Resectable Biliary Tract Cancer: A Systematic Review and Metanalysis.","authors":"Rafael Alvim Pereira, Gabriel Barcellos, Gabriel Lenz, Allan Andresson Lima Pereira, Tiago Biachi de Castria","doi":"10.1002/jso.70169","DOIUrl":"https://doi.org/10.1002/jso.70169","url":null,"abstract":"<p><strong>Background and objectives: </strong>The benefit of neoadjuvant chemotherapy in resectable biliary tract cancer remains unclear.</p><p><strong>Methods: </strong>A systematic review and meta-analysis of 23 studies (n = 11,344) compared neoadjuvant chemotherapy with upfront surgery.</p><p><strong>Results: </strong>Neoadjuvant therapy improved overall survival (HR = 0.69) and R0 resection rates (OR = 1.30) without increasing postoperative morbidity or mortality.</p><p><strong>Conclusions: </strong>Neoadjuvant chemotherapy may improve survival and surgical outcomes in resectable biliary tract cancer.</p>","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145804844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of Combined Additional Resections on the Surgical Outcomes of Robot-Assisted Resection of Thymic Epithelial Tumors. 联合附加切除对机器人辅助胸腺上皮肿瘤切除手术效果的影响。
IF 1.9 3区 医学 Q3 ONCOLOGY Pub Date : 2025-12-18 DOI: 10.1002/jso.70162
Benedikt Niedermaier, Nabil Khan, Florian Eichhorn, Maria Zehentmeier, Heidrun Grosch, Raffaella Griffo, Alessio Campisi, Antonia Margineanu, Michael Allgäuer, Petros Christopoulos, Michael Thomas, Hauke Winter, Martin E Eichhorn

Background and objectives: Robot-assisted thoracoscopy (RATS) is rapidly emerging as the preferred approach for the resection of thymic epithelial tumors (TET). Current challenges include the role of RATS in locally advanced disease and combined additional resections.

Methods: This single-center study included all consecutive robot-assisted surgeries for TET performed between 2018 and 2024. We report perioperative outcomes and findings from a large center for robotic surgery center.

Results: One hundred and forty-three patients underwent RATS for the resection of histologically confirmed TET, including 130 (91%) patients with thymoma and 13 (9%) patients with thymic carcinoma. The median tumor size was 54 mm (35.5-75) and most patients presented in a localized stage of disease, with 120 patients (83.9%) in TNM stage I (TNM 8th edition). The conversion rate to open surgery was 4.2% and R0 resection was achieved in 134 (93.7%) patients. Combined extended resections that included lung, pericardium or great vessels were performed in 44 (30.8%) patients and were the only independent predictor of postoperative complications in a multivariable logistic regression model (OR 2.87; p = 0.03).

Conclusions: Robot-assisted surgery is feasible and without unexpected safety concerns for TET. Combined extended resections, often necessary for locally advanced disease, are a significant predictor of postoperative complications.

背景和目的:机器人辅助胸腔镜(RATS)正迅速成为胸腺上皮肿瘤(TET)切除术的首选方法。目前的挑战包括大鼠在局部晚期疾病中的作用和联合额外切除。方法:这项单中心研究包括2018年至2024年期间进行的所有连续的TET机器人辅助手术。我们报告一个大型机器人手术中心的围手术期结果和发现。结果:143例经组织学证实的TET患者行大鼠切除术,其中胸腺瘤130例(91%),胸腺癌13例(9%)。肿瘤中位大小为54 mm(35.5-75),大多数患者表现为局部分期,其中120例(83.9%)患者为TNM I期(TNM第8版)。开腹转换率为4.2%,134例(93.7%)患者完成R0切除术。在多变量logistic回归模型中,44例(30.8%)患者进行了包括肺、心包或大血管在内的联合扩展切除,这是术后并发症的唯一独立预测因素(or 2.87; p = 0.03)。结论:机器人辅助手术是可行的,并且没有意外的安全问题。联合扩大切除,通常是局部晚期疾病所必需的,是术后并发症的重要预测因素。
{"title":"Impact of Combined Additional Resections on the Surgical Outcomes of Robot-Assisted Resection of Thymic Epithelial Tumors.","authors":"Benedikt Niedermaier, Nabil Khan, Florian Eichhorn, Maria Zehentmeier, Heidrun Grosch, Raffaella Griffo, Alessio Campisi, Antonia Margineanu, Michael Allgäuer, Petros Christopoulos, Michael Thomas, Hauke Winter, Martin E Eichhorn","doi":"10.1002/jso.70162","DOIUrl":"https://doi.org/10.1002/jso.70162","url":null,"abstract":"<p><strong>Background and objectives: </strong>Robot-assisted thoracoscopy (RATS) is rapidly emerging as the preferred approach for the resection of thymic epithelial tumors (TET). Current challenges include the role of RATS in locally advanced disease and combined additional resections.</p><p><strong>Methods: </strong>This single-center study included all consecutive robot-assisted surgeries for TET performed between 2018 and 2024. We report perioperative outcomes and findings from a large center for robotic surgery center.</p><p><strong>Results: </strong>One hundred and forty-three patients underwent RATS for the resection of histologically confirmed TET, including 130 (91%) patients with thymoma and 13 (9%) patients with thymic carcinoma. The median tumor size was 54 mm (35.5-75) and most patients presented in a localized stage of disease, with 120 patients (83.9%) in TNM stage I (TNM 8th edition). The conversion rate to open surgery was 4.2% and R0 resection was achieved in 134 (93.7%) patients. Combined extended resections that included lung, pericardium or great vessels were performed in 44 (30.8%) patients and were the only independent predictor of postoperative complications in a multivariable logistic regression model (OR 2.87; p = 0.03).</p><p><strong>Conclusions: </strong>Robot-assisted surgery is feasible and without unexpected safety concerns for TET. Combined extended resections, often necessary for locally advanced disease, are a significant predictor of postoperative complications.</p>","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145775001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Examining Surgical Margins in the Excision of Basal Cell Carcinoma and Squamous Cell Carcinoma: Evaluating Pre-Excision, Post-Excision, Post-Fixation, and Pathological Margin Measurements. 检查基底细胞癌和鳞状细胞癌切除的手术边缘:评估切除前、切除后、固定后和病理边缘测量。
IF 1.9 3区 医学 Q3 ONCOLOGY Pub Date : 2025-12-18 DOI: 10.1002/jso.70163
Özgür Agdoğan, Ayşegül İsal Arslan

Introduction: There remains uncertainty regarding whether the determination of a safe margin is the responsibility of the surgeon or the pathologist during the pathological analysis of tissue from various procedures. This study aims to assess the alterations in surgical margin dimensions of tissue 1 h post-excision, following 24 h of formalin fixation, and pathological in comparison to the margin determined prior to excision.

Patients and methods: Measurements and mean values were taken for each specimen at four stages: before excision, 1 h post-excision, after 24 h of 10% formalin fixation, and following pathologic examination. BCCs and SCCs were evaluated independently, and statistical analyses were performed to assess changes in the measurements of the specimens.

Results: Table 1 illustrates highly significant reductions of the order of 70%-80% overall in the measured specimen margin widths over time for all of the categories measured.

Conclusion: Excised skin cancers were found to undergo significant shrinkage at every stage of pathological evaluation, resulting in a surgical margin significantly narrower than the safety margin initially determined. We have clarified what the surgical margin reported by the dermatopathologist actually means. In this way, it was aimed to eliminate the disagreement between the surgeon and the pathologist and to prevent the need for additional surgery and morbidities.

导言:在对各种手术组织进行病理分析时,安全边缘的确定是外科医生的责任还是病理学家的责任仍然存在不确定性。本研究旨在评估切除后1小时,福尔马林固定24小时后组织手术边缘尺寸的变化,以及与切除前确定的边缘相比的病理变化。患者和方法:每个标本在四个阶段测量和平均值:切除前、切除后1小时、10%福尔马林固定24小时后和病理检查后。对bcc和SCCs进行独立评估,并进行统计分析以评估标本测量值的变化。结果:表1显示了随着时间的推移,测量的所有类别的标本边缘宽度总体上有70%-80%的显著减少。结论:在病理评估的每个阶段,切除的皮肤癌都发生了明显的收缩,导致手术边界比最初确定的安全边界明显变窄。我们已经澄清了皮肤病理学家报告的手术切缘实际上是什么意思。通过这种方式,它旨在消除外科医生和病理学家之间的分歧,并防止需要额外的手术和发病率。
{"title":"Examining Surgical Margins in the Excision of Basal Cell Carcinoma and Squamous Cell Carcinoma: Evaluating Pre-Excision, Post-Excision, Post-Fixation, and Pathological Margin Measurements.","authors":"Özgür Agdoğan, Ayşegül İsal Arslan","doi":"10.1002/jso.70163","DOIUrl":"https://doi.org/10.1002/jso.70163","url":null,"abstract":"<p><strong>Introduction: </strong>There remains uncertainty regarding whether the determination of a safe margin is the responsibility of the surgeon or the pathologist during the pathological analysis of tissue from various procedures. This study aims to assess the alterations in surgical margin dimensions of tissue 1 h post-excision, following 24 h of formalin fixation, and pathological in comparison to the margin determined prior to excision.</p><p><strong>Patients and methods: </strong>Measurements and mean values were taken for each specimen at four stages: before excision, 1 h post-excision, after 24 h of 10% formalin fixation, and following pathologic examination. BCCs and SCCs were evaluated independently, and statistical analyses were performed to assess changes in the measurements of the specimens.</p><p><strong>Results: </strong>Table 1 illustrates highly significant reductions of the order of 70%-80% overall in the measured specimen margin widths over time for all of the categories measured.</p><p><strong>Conclusion: </strong>Excised skin cancers were found to undergo significant shrinkage at every stage of pathological evaluation, resulting in a surgical margin significantly narrower than the safety margin initially determined. We have clarified what the surgical margin reported by the dermatopathologist actually means. In this way, it was aimed to eliminate the disagreement between the surgeon and the pathologist and to prevent the need for additional surgery and morbidities.</p>","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145775053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Multimodal Care and Outcomes of Pancreatic Cancer Patients Are Influenced by Factors Beyond Biology: A Population-Based Study From Louisiana Tumor Registry. 胰腺癌患者的多模式护理和预后受生物学以外因素的影响:一项来自路易斯安那州肿瘤登记处的基于人群的研究
IF 1.9 3区 医学 Q3 ONCOLOGY Pub Date : 2025-12-18 DOI: 10.1002/jso.70129
Aimée Galatas, Hannah R Malinosky, Andrew G Chapple, Sydney McManus, Ann Byerley, Ethan Littlefield, Sarah Hemelt, John Lyons, Denise Danos, Omeed Moaven

Background: This study aims to evaluate potential disparities in multimodal treatment and its impact on outcomes among pancreatic cancer patients in Louisiana.

Methods: Data on pancreatic cancer cases diagnosed between 2000 and 2020 were obtained from the Louisiana Tumor Registry. Bivariate relationships were assessed via Chi-square tests. Treatment was modeled with logistic regression models. Time-to-treatment was modeled with negative binomial regression models. Overall survival was analyzed with Cox proportional hazards models. Results are reported as odds ratio (OR), rate ratios (RR), hazards ratio (HR), and 95% Wald confidence intervals.

Results: A total of 8,466 patients with pancreatic cancer were included. A significantly higher proportion of nonmetastatic cases received therapy compared to metastatic cases. Non-Hispanic Black patients with nonmetastatic disease experienced a significantly longer time to treatment compared to Non-Hispanic White patients. In the metastatic model, uninsured patients and those with Medicaid had the highest odds of not receiving therapy. Primary resection was a strong predictor of improved survival. Nonsurgical therapy also contributed to better outcomes.

Conclusion: The findings of this study are instrumental in designing a more granular investigation of multi-level determinants to identify the actionable items driving the observed disparities associated with worse outcomes.

背景:本研究旨在评估路易斯安那州胰腺癌患者多模式治疗的潜在差异及其对预后的影响。方法:2000年至2020年间诊断的胰腺癌病例数据来自路易斯安那州肿瘤登记处。通过卡方检验评估双变量关系。采用logistic回归模型对治疗进行建模。治疗时间采用负二项回归模型。采用Cox比例风险模型分析总生存率。结果以比值比(OR)、比率比(RR)、危险比(HR)和95% Wald置信区间报告。结果:共纳入8466例胰腺癌患者。与转移病例相比,接受治疗的非转移病例比例明显更高。非西班牙裔黑人患者与非西班牙裔白人患者相比,非转移性疾病的治疗时间明显更长。在转移模型中,没有保险的患者和有医疗补助的患者不接受治疗的几率最高。初次切除是提高生存率的有力预测指标。非手术治疗也有助于改善预后。结论:本研究的发现有助于设计更细致的多层次决定因素调查,以确定驱动观察到的与较差结果相关的差异的可操作项目。
{"title":"Multimodal Care and Outcomes of Pancreatic Cancer Patients Are Influenced by Factors Beyond Biology: A Population-Based Study From Louisiana Tumor Registry.","authors":"Aimée Galatas, Hannah R Malinosky, Andrew G Chapple, Sydney McManus, Ann Byerley, Ethan Littlefield, Sarah Hemelt, John Lyons, Denise Danos, Omeed Moaven","doi":"10.1002/jso.70129","DOIUrl":"https://doi.org/10.1002/jso.70129","url":null,"abstract":"<p><strong>Background: </strong>This study aims to evaluate potential disparities in multimodal treatment and its impact on outcomes among pancreatic cancer patients in Louisiana.</p><p><strong>Methods: </strong>Data on pancreatic cancer cases diagnosed between 2000 and 2020 were obtained from the Louisiana Tumor Registry. Bivariate relationships were assessed via Chi-square tests. Treatment was modeled with logistic regression models. Time-to-treatment was modeled with negative binomial regression models. Overall survival was analyzed with Cox proportional hazards models. Results are reported as odds ratio (OR), rate ratios (RR), hazards ratio (HR), and 95% Wald confidence intervals.</p><p><strong>Results: </strong>A total of 8,466 patients with pancreatic cancer were included. A significantly higher proportion of nonmetastatic cases received therapy compared to metastatic cases. Non-Hispanic Black patients with nonmetastatic disease experienced a significantly longer time to treatment compared to Non-Hispanic White patients. In the metastatic model, uninsured patients and those with Medicaid had the highest odds of not receiving therapy. Primary resection was a strong predictor of improved survival. Nonsurgical therapy also contributed to better outcomes.</p><p><strong>Conclusion: </strong>The findings of this study are instrumental in designing a more granular investigation of multi-level determinants to identify the actionable items driving the observed disparities associated with worse outcomes.</p>","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145775026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Surgical Oncology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1